How do people make sense of the epiphanies when they experience them? Pexels

It might be just the right word from your boss. It might be a phone call with a trusted friend. Or it might be waking up one morning and just knowing. There's no way to predict what will spark an epiphany that changes the way you see the world. But their power can be so far-reaching, they often leave us wondering where on earth that brilliant idea came from — and how we can find more.

Studying the mental processes behind epiphanies is especially hard because these flashes of insight are usually linked with unconscious mental processing and incubation, often during time periods when one may not seem to be thinking about a problem at all. In this way, epiphanies seem to arrive effortlessly.

So how do people make sense of the epiphanies when they experience them? In a set of unprecedented studies, Rice Business professor Erik Dane set out to find answers, first examining people who'd experienced general epiphanies, then analyzing a set of accounts of work- and career-related epiphanies themselves.

The research

In his first study, Dane surveyed more than 500 randomly selected people to ask them about their experiences with epiphanies, which he defined as a sudden and abrupt insight and/or change in perspective that transforms the individual.

Subjects who said they'd experienced epiphanies reported what they'd been doing beforehand, the feelings and insight associated with the epiphany and how they thought they'd changed afterward. Interestingly, though this survey wasn't limited to career- or work-related epiphanies, 20 percent of the responses related directly to these topics.

In the second study, Dane interviewed 22 professionals, asking them about distinct work- or career-related epiphanies, most of which resolved a nagging problem. After analyzing the transcripts of these interviews, Dane developed a set of theoretical categories describing the varieties of reactions an epiphany might spark.

People generally perceive and analyze their epiphanies in similar ways, Dane found. He categorized these into four dimensions: a person's emotional reaction to the experience of the epiphany, the question of how the epiphany arose, the circumstances that preceded the insight and a person's observations about how ready they were to experience change through an epiphany.

The findings

The typical first reaction to an epiphany, Dane says, is a sudden and emotionally charged release from a problem or tension. We've all been there: a stressful work situation that seems to offer no way out, followed by a dazzling solution that appears from the clouds. It's that suddenness that leads to the second typical reaction: a sense of astonishment due to the nonconscious nature of the insight's arrival. Feeling dumbfounded for a prolonged time isn't useful, though, so we usually start examining the factors surrounding the epiphany, including our own readiness to change.

What does this imply for workplace? After all, not every problem can or even ought to be solved by epiphany. At the same time, Dane notes, epiphanies can provide critical impetus to move forward.

Interestingly, his findings hint that one can increase the chances of having an epiphany. Though further research is required, Dane concludes that epiphanies most commonly arrive when people are open to the prospect of experiencing a major change. When something is mentally constraining us, on the other hand, eureka moments keep their distance.

The conclusion

As a worker, Dane suggests, you can open space for epiphanies by being actively aware of your surroundings. Look closely at your workplace, your constellation of coworkers and your place within the system. Perceived mindfully, these details may set the stage for problem-solving in a less focused moment.

If you're a mentor or a supervisor hoping to spark epiphanies in your work team, try applying this principle at work: Rather than laying out specific targets and attacking them head-on, aim for an environment that allows for mindful engagement, one that includes the problems that feature in your long-term goals and resonate with your workers' concerns and interests. Cultivating this environment and granting workers time and space to wander through it may lead, like a divining rod, to fresh sources of wisdom.

------

This article originally appeared on Rice Business Wisdom.

Erik Dane is a distinguished associate professor of management (organizational behavior) at Jones Graduate School of Business at Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

CPRIT CEO: Houston’s $2B in funding is transforming cancer research and prevention

fighting cancer

With its plethora of prestigious health care organizations like the University of Texas MD Anderson Cancer Center, UTHealth Houston, and the Baylor College of Medicine, Houston sits at the heart of cancer research and prevention in Texas.

Of course, it takes piles of cash to support Houston’s status as the state’s hub for cancer research and prevention. Much of that money comes from the Cancer Prevention and Research Institute of Texas (CPRIT).

Data supplied by CPRIT shows organizations in Harris County gained $2.3 billion in institute funding from 2009 through 2025, or nearly $145 million per year. That represents almost 60 percent of the roughly $4 billion that CPRIT has granted to Texas institutions over a 16-year period.

“The life sciences ecosystem that has developed and changed in Houston is phenomenal,” Kristen Doyle, who became the agency’s CEO in July 2024, tells InnovationMap. “In the next decade, we will look back and see a great transformation.”

That ecosystem includes more than 1,100 life sciences and biotech companies, according to the Greater Houston Partnership.

Houston plays critical role in clinical trials

Texas voters approved the creation of CPRIT in 2007. Twelve years later, voters agreed to earmark an extra $3 billion for CPRIT, bringing the state agency’s total investment in cancer research and prevention to $6 billion.

To date, CPRIT money has gone toward recruiting 344 cancer researchers to Texas (mainly to Houston) and has supported cancer prevention services for millions of Texans in the state’s 254 counties. CPRIT funding has also helped establish, expand, or relocate 25 cancer-focused companies. In Houston, MD Anderson ranks as the No. 1 recipient of CPRIT funding.

Regarding cancer research, Doyle says Houston plays a critical role in clinical trials.

“[Clinical trials are] something that CPRIT has focused on more and more. Brilliant discoveries are crucial to this whole equation of solving the cancer problem,” Doyle says. “But if those brilliant ideas stay in the labs, then we’ve all failed.”

Researchers conduct more clinical trials in Houston than anywhere else in the U.S., the Greater Houston Partnership says.

Doyle, a 20-year survivor of leukemia, notes that a minority of eligible patients participate in clinical trials for cancer treatments, “and that’s one of the reasons that it takes so long to get a promising drug to market.”

An estimated 7 percent of cancer patients sign up for clinical trials, according to a study published in 2024 in the Journal of Clinical Oncology.

MD Anderson takes on cancer prevention

Doyle also notes that Houston is leading the charge in cancer prevention.

“We get some national recognition for programs that have been developed in Houston that then can be replicated in other parts of the country,” she says.

Much of the work in Houston focusing on cancer prevention takes place at MD Anderson. The hospital reports that it has received more than $725 million from the CPRIT since 2007, representing approximately 18 percent of CPRIT’s total awards.

“These efforts can have profound impact on the lives of patients and their families, and this funding ensures our exemplary clinicians and scientists can continue working together to drive breakthroughs that advance our mission to end cancer,” Dr. Giulio Draetta, chief scientific officer at MD Anderson, said in a November news release, following the most recent CPRIT award for the hospital totalling more than $29 million.

CPRIT funding for Houston institutions supplements the more than $4.5 billion in federal funding for health and life sciences research and innovations that the Houston area received from 2020 to 2024, according to the Greater Houston Partnership.

“We are curing cancer every single day,” Doyle says of CPRIT. “Every step that we are taking — whether that’s funding great ideas or funding the clinical trials that are bringing promising drugs to Texas and to the world — we are making a difference.”

Houston energy tech co. breaks ground on low-cost hydrogen pilot plant

Coming Soon

Houston’s Lummus Technology and Advanced Ionics have broken ground on their hydrogen pilot plant at Lummus’ R&D facility in Pasadena, Texas.

The plant will support Advanced Ionics’ cutting-edge electrolyzer technology, which aims to deliver high-efficiency hydrogen production with reduced energy requirements.

“By demonstrating Advanced Ionics’ technology at our state-of-the-art R&D facility, we are leveraging the expertise of our scientists and R&D team, plus our proven track record of developing breakthrough technologies,” Leon de Bruyn, president and CEO of Lummus, said in a news release. “This will help us accelerate commercialization of the technology and deliver scalable, cost-effective and sustainable green hydrogen solutions to our customers.”

Advanced Ionics is a Milwaukee-based low-cost green hydrogen technology provider. Its electrolyzer converts process and waste heat into green hydrogen for less than a dollar per kilogram, according to the company. The platform's users include industrial hydrogen producers looking to optimize sustainability at an affordable cost.

Lummus, a global energy technology company, will operate the Advanced Ionics electrolyzer and manage the balance of plant systems.

In 2024, Lummus and Advanced Ionics established their partnership to help advance the production of cost-effective and sustainable hydrogen technology. Lummus Venture Capital also invested an undisclosed amount into Advanced Ionics at the time.

“Our collaboration with Lummus demonstrates the power of partnerships in driving the energy transition forward,” Ignacio Bincaz, CEO of Advanced Ionics, added in the news release. “Lummus serves as a launchpad for technologies like ours, enabling us to validate performance and integration under real-world conditions. This milestone proves that green hydrogen can be practical and economically viable, and it marks another key step toward commercial deployment.”

---

This article originally appeared on EnergyCapitalHTX.com.

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.